Clinical trials in Ridgeland, MS

17 recruiting studies have a site in or near Ridgeland, MS, Mississippi.

Top conditions here

All conditions

Showing 17 of 17 studies

RecruitingPhase 3NCT07654374

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

Gulfport, MS · Ridgeland, MS · +72 more sites

RecruitingPhase 3NCT07674654

A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

Sponsor: Kallyope Inc.

Gulfport, MS · Ridgeland, MS · +111 more sites

RecruitingPhase 3NCT07181109

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

Sponsor: Alnylam Pharmaceuticals

Jackson, MS · Olive Branch, MS · Port Gibson, MS · +270 more sites

RecruitingPhase 3NCT07845500

A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity

Sponsor: Pfizer

Ridgeland, MS · +15 more sites

RecruitingPhase 4NCT07609914

A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine

Sponsor: Pfizer

Ridgeland, MS · +20 more sites

RecruitingPhase 3NCT07667803

A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

Sponsor: AstraZeneca

Ridgeland, MS · +55 more sites

RecruitingPhase 3NCT06810505

A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

Sponsor: AbbVie

Ridgeland, MS · +31 more sites

RecruitingPhase 3NCT05711394

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

Sponsor: AbbVie

Ridgeland, MS · +41 more sites

RecruitingPhase 2NCT06343298

To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension

Sponsor: E-Star BioTech, LLC

Ridgeland, MS · +22 more sites

RecruitingPhase 2NCT07340320

A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus

Sponsor: Corxel Pharmaceuticals

Ridgeland, MS · +33 more sites

RecruitingPhase 3NCT05125302

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

Sponsor: AbbVie

Petal, MS · Ridgeland, MS · +123 more sites

RecruitingPhase 3NCT07662109

A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus

Sponsor: AstraZeneca

Ridgeland, MS · +39 more sites

RecruitingPhase 3NCT07645924

A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

Sponsor: Kallyope Inc.

Gulfport, MS · Ridgeland, MS · +111 more sites

RecruitingPhase 3NCT07654361

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

Gulfport, MS · Ridgeland, MS · +69 more sites

RecruitingPhase not listedNCT06880055

Shield Post-Approval Study Protocol

Sponsor: Guardant Health, Inc.

Ridgeland, MS · +68 more sites

RecruitingPhase 1 / Phase 2NCT06649110

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

Sponsor: Novartis Pharmaceuticals

Ridgeland, MS · +19 more sites

Not yet recruitingPhase 3NCT07881432

A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes

Sponsor: Eli Lilly and Company

Ridgeland, MS · +54 more sites

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.